Masaaki Murakami

Masaaki Murakami

Auto-generated profile, based on publicly available information

Masaaki Murakami

Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo 060-0815, Japan

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Inflammation and Regeneration
Verified
Journal Article
Open access
PDF file
SHShintaro Hojyo
Shintaro Hojyo
MUMona Uchida
Mona Uchida
KTKumiko Tanaka
Kumiko Tanaka
RHRie Hasebe
Rie Hasebe
YTYuki Tanaka
Yuki Tanaka
THToshio Hirano
Toshio Hirano
The newly emerging coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, but has rapidly spread all over the world. Some COVID-19 patients encounter a severe symptom of acute respiratory distress syndrome (ARDS) with high mortality. This high severity is dependent on a cytokine storm, most likely induced by the interleukin-6 (IL-6) amplifier, which is hyper-activation machinery that regulates the nuclear factor kappa B (NF-κB) pathway and stimulated by the simultaneous activation of IL-6-signal transducer and activator of transcription 3 (STAT3) and NF-κB signaling in non-immune cells including alveolar epithelial cells and endothelial cells. We hypothesize that IL-6-STAT3 signaling is a promising therapeutic target for the cytokine storm in COVID-19, because IL-6 is a major STAT3 stimulator, particularly during inflammation. We herein review the pathogenic mechanism and potential therapeutic targets of ARDS in COVID-19 patients.

1 February 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MFMunezumi Fujita
Munezumi Fujita
YYYuhei Yamamoto
Yuhei Yamamoto
JJJing-Jing Jiang
Jing-Jing Jiang
TAToru Atsumi
Toru Atsumi
YTYuki Tanaka
Yuki Tanaka
MMMasaaki Murakami
Masaaki Murakami

1 February 2015 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MHMasaya Harada
Masaya Harada
DKDaisuke Kamimura
Daisuke Kamimura
YAYasunobu Arima
Yasunobu Arima
HKHitoshi Kohsaka
Hitoshi Kohsaka
YNYuji Nakatsuji
Yuji Nakatsuji
MMMasaaki Murakami
Masaaki Murakami
In this study, we investigated the relationship between several growth factors and inflammation development. Serum concentrations of epiregulin, amphiregulin, betacellulin, TGF-α, fibroblast growth factor 2, placental growth factor (PLGF), and tenascin C were increased in rheumatoid arthritis patients. Furthermore, local blockades of these growth factors suppressed the development of cytokine-induced arthritis in mice by inhibiting chemokine and IL-6 expressions. We found that epiregulin expression was early and followed by the induction of other growth factors at different sites of the joints. The same growth factors then regulated the expression of epiregulin at later time points of the arthritis. These growth factors were increased in patients suffering from multiple sclerosis (MS) and also played a role in the development of an MS model, experimental autoimmune encephalomyelitis. The results suggest that the temporal expression of growth factors is involved in the inflammation development seen in several diseases, including rheumatoid arthritis and MS. Therefore, various growth factor pathways might be good therapeutic targets for various inflammatory diseases.

11 August 2015 in eLife
Verified
Journal Article
Open access
YAYasunobu Arima
Yasunobu Arima
DKDaisuke Kamimura
Daisuke Kamimura
TAToru Atsumi
Toru Atsumi
MHMasaya Harada
Masaya Harada
TKTadafumi Kawamoto
Tadafumi Kawamoto
MMMasaaki Murakami
Masaaki Murakami
Although pain is a common symptom of various diseases and disorders, its contribution to disease pathogenesis is not well understood. Here we show using murine experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS), that pain induces EAE relapse. Mechanistic analysis showed that pain induction activates a sensory-sympathetic signal followed by a chemokine-mediated accumulation of MHC class II+CD11b+ cells that showed antigen-presentation activity at specific ventral vessels in the fifth lumbar cord of EAE-recovered mice. Following this accumulation, various immune cells including pathogenic CD4+ T cells recruited in the spinal cord in a manner dependent on a local chemokine inducer in endothelial cells, resulting in EAE relapse. Our results demonstrate that a pain-mediated neural signal can be transformed into an inflammation reaction at specific vessels to induce disease relapse, thus making this signal a potential therapeutic target.

13 December 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TITakeshi Inoue
Takeshi Inoue
RSRyo Shinnakasu
Ryo Shinnakasu
CKChie Kawai
Chie Kawai
HYHiromi Yamamoto
Hiromi Yamamoto
SSShuhei Sakakibara
Shuhei Sakakibara
TKTomohiro Kurosaki
Tomohiro Kurosaki
In contrast to a second dose of the SARS-CoV-2 mRNA vaccine, a third dose elicits potent neutralizing activity against the Omicron variant. To address the underlying mechanism for this differential antibody response, we examined spike receptor-binding domain (RBD)–specific memory B cells in vaccinated individuals. Frequency of Omicron-reactive memory B cells increased ∼9 mo after the second vaccine dose. These memory B cells show an altered distribution of epitopes from pre-second memory B cells, presumably due to an antibody feedback mechanism. This hypothesis was tested using mouse models, showing that an addition or a depletion of RBD-induced serum antibodies results in a concomitant increase or decrease, respectively, of Omicron-reactive germinal center (GC) and memory B cells. Our data suggest that pre-generated antibodies modulate the selection of GC and subsequent memory B cells after the second vaccine dose, accumulating more Omicron-reactive memory B cells over time, which contributes to the generation of Omicron-neutralizing antibodies elicited by the third vaccine dose.

15 August 2017 in eLife
Verified
Journal Article
Open access
YAYasunobu Arima
Yasunobu Arima
TOTakuto Ohki
Takuto Ohki
NNNaoki Nishikawa
Naoki Nishikawa
KHKotaro Higuchi
Kotaro Higuchi
MOMitsutoshi Ota
Mitsutoshi Ota
MMMasaaki Murakami
Masaaki Murakami
Impact of stress on diseases including gastrointestinal failure is well-known, but molecular mechanism is not understood. Here we show underlying molecular mechanism using EAE mice. Under stress conditions, EAE caused severe gastrointestinal failure with high-mortality. Mechanistically, autoreactive-pathogenic CD4+ T cells accumulated at specific vessels of boundary area of third-ventricle, thalamus, and dentate-gyrus to establish brain micro-inflammation via stress-gateway reflex. Importantly, induction of brain micro-inflammation at specific vessels by cytokine injection was sufficient to establish fatal gastrointestinal failure. Resulting micro-inflammation activated new neural pathway including neurons in paraventricular-nucleus, dorsomedial-nucleus-of-hypothalamus, and also vagal neurons to cause fatal gastrointestinal failure. Suppression of the brain micro-inflammation or blockage of these neural pathways inhibited the gastrointestinal failure. These results demonstrate direct link between brain micro-inflammation and fatal gastrointestinal disease via establishment of a new neural pathway under stress. They further suggest that brain micro-inflammation around specific vessels could be switch to activate new neural pathway(s) to regulate organ homeostasis.